140 related articles for article (PubMed ID: 32162400)
41. Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma.
Osada H; Okazawa T; Kushida K; Kishimoto M; Ikeda M; Kondo H; Kimura J; Ohmori K
J Vet Med Sci; 2023 Sep; 85(9):1004-1009. PubMed ID: 37532540
[TBL] [Abstract][Full Text] [Related]
42. Long-Term Survival and Glycemic Control with Toceranib Phosphate and Prednisone for a Metastatic Canine Insulinoma.
Flesner BK; Fletcher JM; Smithee T; Boudreaux B
J Am Anim Hosp Assoc; 2019; 55(1):e55105. PubMed ID: 30427714
[TBL] [Abstract][Full Text] [Related]
43. Skin depigmentation associated with toceranib phosphate in a dog.
Cavalcanti JVJ; Hasbach A; Barnes K; Dange RB; Patterson J; Saavedra PV
Vet Dermatol; 2017 Aug; 28(4):400-e95. PubMed ID: 28164401
[TBL] [Abstract][Full Text] [Related]
44. Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.
Kovac RL; Ballash G; Fenger J; London C; Warry E
J Vet Intern Med; 2018 Nov; 32(6):2061-2068. PubMed ID: 30353992
[TBL] [Abstract][Full Text] [Related]
45. Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia).
Elliott JW; Swinbourne F; Parry A; Baines L
J Small Anim Pract; 2017 Jul; 58(7):416-418. PubMed ID: 28199021
[TBL] [Abstract][Full Text] [Related]
46. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Smith AD; Lieber ML; Shah SN
AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
[TBL] [Abstract][Full Text] [Related]
47. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review.
Frezoulis P; Harper A
Vet Comp Oncol; 2022 Jun; 20(2):362-371. PubMed ID: 34981886
[TBL] [Abstract][Full Text] [Related]
48. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
Cowey CL; Fielding JR; Rathmell WK
Urology; 2010 May; 75(5):1108-13.e1. PubMed ID: 19931124
[TBL] [Abstract][Full Text] [Related]
49. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
[TBL] [Abstract][Full Text] [Related]
50. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
Rossi F; Sabattini S; Vascellari M; Marconato L
Vet Comp Oncol; 2018 Dec; 16(4):497-504. PubMed ID: 29806156
[TBL] [Abstract][Full Text] [Related]
51. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia.
Alonso-Miguel D; García-San José P; González Sanz S; Clarés Moral I; Pérez-Alenza MD
N Z Vet J; 2021 Jul; 69(4):234-239. PubMed ID: 33944682
[TBL] [Abstract][Full Text] [Related]
53. Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017).
Elliott JW
J Am Vet Med Assoc; 2019 Apr; 254(8):960-966. PubMed ID: 30938616
[TBL] [Abstract][Full Text] [Related]
54. Computed tomographic-lymphography as a complementary technique for lymph node staging in dogs with malignant tumors of various sites.
Rossi F; Körner M; Suárez J; Carozzi G; Meier VS; Roos M; Rohrer Bley C
Vet Radiol Ultrasound; 2018 Mar; 59(2):155-162. PubMed ID: 29024279
[TBL] [Abstract][Full Text] [Related]
55. DOSIMETRIC CONSEQUENCES OF USING CONTRAST-ENHANCED COMPUTED TOMOGRAPHIC IMAGES FOR INTENSITY-MODULATED STEREOTACTIC BODY RADIOTHERAPY PLANNING.
Yoshikawa H; Roback DM; Larue SM; Nolan MW
Vet Radiol Ultrasound; 2015; 56(6):687-95. PubMed ID: 26242716
[TBL] [Abstract][Full Text] [Related]
56. Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines.
Korec DI; Louke DS; Breitbach JT; Geisler JA; Husbands BD; Fenger JM
BMC Vet Res; 2021 Oct; 17(1):320. PubMed ID: 34600548
[TBL] [Abstract][Full Text] [Related]
57. Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.
de Vos J; Ramos Vega S; Noorman E; de Vos P
Vet Comp Oncol; 2012 Sep; 10(3):206-13. PubMed ID: 22236048
[TBL] [Abstract][Full Text] [Related]
58. Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia.
Pérez ML; Culver S; Owen JL; Dunbar M; Kow K; Breen M; Milner RJ
Anticancer Drugs; 2013 Nov; 24(10):1098-103. PubMed ID: 23995854
[TBL] [Abstract][Full Text] [Related]
59. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
Robat C; London C; Bunting L; McCartan L; Stingle N; Selting K; Kurzman I; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):174-83. PubMed ID: 22235914
[TBL] [Abstract][Full Text] [Related]
60. Synergistic Effect of Toceranib and Nanohydroxyapatite as a Drug Delivery Platform-Physicochemical Properties and In Vitro Studies on Mastocytoma Cells.
Sobierajska P; Serwotka-Suszczak A; Targonska S; Szymanski D; Marycz K; Wiglusz RJ
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
